LY-2452473

DB12573InvestigationalSmall molecule

Ly2452473 is under investigation for the supportive care of Prostate Cancer. Ly2452473 has been investigated for the treatment of Erectile Dysfunction.

Mechanism: Pharmacologically active on Androgen receptor
Curator reviewed
Formula / weight: C₂₂H₂₂N₄O₂ · 374.444 g/mol (avg)
Code names: LY2452473

Resolves to

Compound

UNIIXKW9MYF94YCAS1029692-15-6ChEMBLCHEMBL3542265PubChem24963749

Structure

InChIKeyIHIWYQYVBNODSV-KRWDZBQOSA-NSMILESCC(C)OC(=O)N[C@@H]1CC2=C(C1)C1=CC(=CC=C1N2CC1=CC=CC=N1)C#N

Targets

P10275AR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with LY-2452473, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account